|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||5.14 - 5.50|
|52 Week Range||3.88 - 9.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 13, 2018 - Mar 19, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.25|
SAN DIEGO, Feb. 12, 2018-- Conatus Pharmaceuticals Inc. will host a conference call and webcast presentation at 12:00 p.m. ET on Tuesday, February 20, with liver disease expert Paul Pockros, M.D., director ...
SAN DIEGO, Feb. 05, 2018-- In a presentation and in scheduled meetings with members of the investment community in New York next week, Conatus Pharmaceuticals Inc. President, Chief Executive Officer and ...
When Conatus Pharmaceuticals Inc (NASDAQ:CNAT) released its most recent earnings update (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of itsRead More...
The San Diego-based company said it had a loss of 13 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...
NEW YORK, NY / ACCESSWIRE / November 1, 2017 / Conatus Pharmaceuticals Inc. (NASDAQ: CNAT ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 1, 2017 at 4:30 PM ...
Conatus' (CNAT) progress with lead candidate emricasan might boost the stock in Q3. However, the company's current portfolio shows no approved product and revenue generation.
Conatus (CNAT) secures orphan drug designation for its pipeline candidate, IDN-7314, granted by the EMA. The candidate currently undergoes a phase II study on curing primary sclerosing cholangitis.
Conatus Pharmaceuticals (CNAT) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer.
Conatus' (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in the company's portfolio are a positive step toward driving growth.
David Stemerman is winding down his hedge fund firm to explore a run for governor of Connecticut, according to a letter sent to clients of Conatus Capital Management LP on Tuesday. "Connecticut – home to my family and business – is in crisis," Stemerman wrote in the note, which was viewed by Reuters. The next election for governor in Connecticut is in November 2018.
Conatus (CNAT) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Conatus's (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in its portfolio are a positive step by the company to propel growth.
Conatus (CNAT) reports wider-than-expected loss in Q2. However, revenue beat estimates, courtesy higher collaboration benefits.
On a per-share basis, the San Diego-based company said it had a loss of 19 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...